Direct Scale Up From Clone To 2K GMP Batches

If your fed-batch process is burning bioreactor time on cell growth before production even starts, N-1 perfusion technology is worth a serious look. The pre-stage approach, also called N-1 perfusion, seeds the production bioreactor at a starting cell density of 20–40 x 10⁶ cells/mL, effectively compressing the replicative phase and redirecting cellular resources toward antibody production from the outset.

Syngene's biopharmaceutical development team applied three coordinated process levers: high initial seed density, a blended media strategy to sustain culture viability and limit metabolite accumulation, and fine-tuned aeration, agitation, and temperature controls. The result was a titer increase of 1.5–4.5 times compared to conventional fed-batch, with no compromise to product quality.

What that means practically: lower cost of goods for drug substance and drug product, better suite utilization, and a more scalable path to commercial-scale biologic manufacturing. For organizations under pressure to increase biologic output without proportionally increasing facility footprint, the efficiency gains here are real and measurable.

Access the full case study to evaluate how N-1 perfusion parameters could apply to your upstream process development strategy.